This supports the hypothesis that the KEAP1–Nrf2 pathway plays a significant role in ccRCC subtypes with specific epigenetic changes, suggesting that Nrf2 might be a promising pharmacological target [88]. Here, NFE2L2 is linked to nonpapillary renal cell carcinoma.